Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

New Month, New Year, New Faculty, and New Baby
Author
Howard (Jack) West, MD

Happy new year to everyone, and with the change to January, there will again be some comings and goings of the faculty. I know I can speak for the entire GRACE community when I express my thanks to Dr. Pinder for her great help this past month, and we'll definitely have her back. Fortunately, Dr. Weiss has agreed to continue to participate in our discussions for January as well.

Also ringing in the new year with us will be some faculty who are coming back after relatively short or long absences. The ever-fabulous Dr. Stephanie Harman, head of the Palliative Care Program at Stanford University, is just coming off of maternity leave after having her first baby, Jack (I presume she didn't name him after me, but perhaps she does regard me that highly), in October, so I offer my congratulations and thanks for coming back to work with us while juggling home life and her return to regular work responsibilities.

Dr. Shirish Gadgeel is also a faculty member who has participated here and there in the past few years. He has written a few posts, now more than a year old (in our "classics" section) but was also kind enough to speak at our NSCLC Patient Education Forum in Seattle this past September on management principles for stage III NSCLC. He is a medical oncologist and lung cancer expert at the Barbara Ann Karmanos Cancer Center at Wayne State University in Detroit, and he has also been a friend in the field for many years. I'm very happy to have him participate on a more regular basis in the coming weeks.

I hope you'll find great discussions and valuable answers to your questions.

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.